Last reviewed · How we verify
aspirin and dipyridamole
Aspirin and dipyridamole, marketed by UMC Utrecht, is a well-established drug primarily indicated for stroke prevention. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the loss of exclusivity post-patent expiry, which could significantly impact market share and revenue.
At a glance
| Generic name | aspirin and dipyridamole |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Stroke prevention
Common side effects
- Headache
- Dyspepsia
- Abdominal pain
- Nausea
- Diarrhea
Serious adverse events
- Cerebral hemorrhage
- Intracranial hemorrhage
- Subarachnoid hemorrhage
- Gastric ulceration and perforation
- Coma
- Allergic reaction
Drug interactions
- anticoagulants, antiplatelets, or NSAIDs
- NSAIDs
- adenosinergic agents (e.g., adenosine, regadenoson)
- ACE inhibitors
- acetazolamide
- anagrelide
- anticonvulsants (phenytoin, valproic acid)
- beta blockers
- cholinesterase inhibitors
- diuretics
- methotrexate
- oral hypoglycemics
Key clinical trials
- Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
- Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis (NA)
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） (PHASE4)
- Aggrenox To Treat Acute Covid-19 (PHASE3)
- Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients (PHASE4)
- Genotype Guided Antiplatelet Therapy in Ischemic Stroke (NA)
- Th Tl Xb Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients (NA)
- Antiplatelet Therapy for AIS Patients With Thrombocytopenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin and dipyridamole CI brief — competitive landscape report
- aspirin and dipyridamole updates RSS · CI watch RSS
- UMC Utrecht portfolio CI